Exclusively for Pro Subscribers: This stock is expected to rally nearly 80%
Morsa Images | DigitalVision | Getty Images |
|
|
This little-known California-based biopharmaceutical stock can see its shares rally nearly 80% in the near term, according to Goldman Sachs. Shares of the company's stock were up more than 5% in trading Thursday on the back of Goldman analyst Paul Choi who issued a buy rating for this stock. Subscribe to CNBC Pro to see which stock Goldman is predicting could rally nearly 80%. |
|
|
Here are more of today's top stories, exclusively for CNBC Pro subscribers! Chip stocks have had a tough year — but one looks 'really inviting,' fund manager says
THU, OCTOBER 20 2022 Here are Thursday's biggest analyst calls: Apple, Tesla, Amazon, Dick's, Sunrun, Nike & more
THU, OCTOBER 20 2022 Too cheap? 18 stocks with single-digit P/Es that are expected to rally THU, OCTOBER 20 2022 Goldman says buy this under-the-radar biopharma stock expected to rally nearly 80%
THU, OCTOBER 20 2022 Bernstein says Musk was 'curt' and 'almost dismissive' on earnings call, sees stock dropping nearly 30% THU, OCTOBER 20 2022 Should you trust this recent market rally? Here's how Wall Street is advising their clients
THU, OCTOBER 20 2022 |
|
|
| Like getting these emails? Subscribe to CNBC Pro today and get access to unlimited Pro articles, access to Pro live events, stock tips, and money-making investment ideas. |
|
|
© 2022 CNBC LLC. All rights reserved. A property of NBCUniversal. 900 Sylvan Avenue, Englewood Cliffs, NJ 07632 Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes and Market Data and Analysis. Data also provided by THOMSON REUTERS |
|
|
|
Tidak ada komentar:
Posting Komentar